专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明专利

JP2006006329A Promotion or inhibition of angiogenesis and cardiovascularization 有权
标题翻译：促进或抑制血液生成和心血管化
公开(公告)号：JP2006006329A
公开(公告)日：2006-01-12
申请号：JP2005180188
申请日：2005-06-21
申请人： Genentech Inc , ジェネンテック・インコーポレーテッドGenentech,Inc.
发明人： ASHKENAZI AVI J , BAKER KEVIN P , FERRARA NAPOLEONE , GERBER HANSPETER , HILLAN KENNETH J , GODDARD AUDREY , PAUL J GODOWSKI , GURNEY AUSTIN L , KLEIN ROBERT D , SOPHIA S KUO , PAONI NICHOLAS F , SMITH VICTORIA , WATANABE COLIN K , WILLIAMS P MICKEY , WOOD WILLIAM I
IPC分类号： C12N15/09 , G01N33/50 , A61K20060101 , A61K31/7088 , A61K31/711 , A61K38/00 , A61K38/17 , A61K39/395 , A61K45/00 , A61K45/06 , A61K48/00 , A61P7/00 , A61P9/00 , A61P9/04 , A61P9/10 , A61P17/00 , A61P17/02 , A61P35/00 , C07K14/47 , C07K14/515 , C07K14/52 , C07K16/18 , C07K16/22 , C07K16/24 , C07K16/46 , C07K19/00 , C12N1/15 , C12N1/19 , C12N1/21 , C12N5/10 , C12N7/00 , C12N15/11 , C12N15/12 , C12N15/867 , C12P21/02 , C12P21/08 , C12Q1/02 , C12Q1/68 , C12R1/19 , C12R1/645 , C12R1/93 , G01N33/15 , G01N33/53 , G01N33/68
CPC分类号： C12N9/6408 , A61K38/00 , C07K14/47 , C07K14/4703 , C07K16/18 , C12N2799/026 , C12Y304/21034 , G01N2800/32
摘要： PROBLEM TO BE SOLVED: To provide compositions and methods for stimulating or inhibiting angiogenesis and/or cardiovascularization in mammals, including humans. SOLUTION: Pharmaceutical compositions are based on polypeptides or antagonists thereto that have been identified for one or more of these uses. Disorders that can be diagnosed, prevented, or treated by the compositions herein include trauma such as wounds, various cancers, and disorders of the vessels including atherosclerosis and cardiac hypertrophy. In addition, provided are novel polypeptides and nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides, and methods for producing the polypeptides. COPYRIGHT: (C)2006,JPO&NCIPI
摘要翻译：待解决的问题：提供用于刺激或抑制包括人在内的哺乳动物的血管发生和/或心血管化的组合物和方法。解决方案：药物组合物基于已经被鉴定为一种或多种这些用途的多肽或其拮抗剂。可以通过本文组合物诊断，预防或治疗的疾病包括创伤，例如创伤，各种癌症和血管障碍，包括动脉粥样硬化和心脏肥大。此外，提供了编码那些多肽的新型多肽和核酸分子。本文还提供了包含那些核酸序列的载体和宿主细胞，包含与异源多肽序列融合的多肽的嵌合多肽分子，与多肽结合的抗体，以及用于产生多肽的方法。版权所有（C）2006，JPO＆NCIPI

2. 发明专利

JP2009148258A Use of Gdnf and gdnf receptor 审中-公开
标题翻译： GDNF和GDNF受体的使用
公开(公告)号：JP2009148258A
公开(公告)日：2009-07-09
申请号：JP2008320112
申请日：2008-12-16
申请人： Genentech Inc , ジェネンテック・インコーポレーテッドGenentech,Inc.
发明人： KLEIN ROBERT D , MOORE MARK W , ROSENTHAL ARNON , RYAN ANNE M
IPC分类号： C12N15/09 , A01K67/027 , A61K38/00 , A61P1/00 , A61P13/12 , A61P43/00 , C07K14/705 , C07K16/28 , C07K19/00 , C12N1/15 , C12N1/19 , C12N1/21 , C12N5/10 , C12P21/02 , C12P21/08 , C12Q1/02
摘要： PROBLEM TO BE SOLVED: To provide GDNFR α, GDNFR α extracellular domain (ECD), GDNFR α variant, chimeric GDNFR α (e.g., GDNFR α immunoadhesin) and antibodies which bind thereto (including agonist and neutralizing antibodies). SOLUTION: The method to modulate cell activity and survival by response to GDNFR α-ligands, for example GDNF, comprises providing GDNFR α to a cell. The method for treating kidney diseases comprises using GDNFR α, GDNF or an agonist thereof separately or in complex. COPYRIGHT: (C)2009,JPO&INPIT
摘要翻译：要解决的问题：提供GDNFRα，GDNFRα细胞外结构域（ECD），GDNFRα变体，嵌合GDNFRα（例如，GDNFRα免疫粘附素）和与其结合的抗体（包括激动剂和中和抗体）。解决方案：通过对GDNFRα-配体（例如GDNF）的应答来调节细胞活性和存活的方法包括向细胞提供GDNFRα。治疗肾脏疾病的方法包括使用GDNFRα，GDNF或其分别或复合物的激动剂。版权所有（C）2009，JPO＆INPIT

3. 发明专利

JP2009171974A GFRα3 AND ITS USE 审中-公开
标题翻译： GFRalpha3及其用途
公开(公告)号：JP2009171974A
公开(公告)日：2009-08-06
申请号：JP2009058421
申请日：2009-03-11
申请人： Genentech Inc , ジェネンテック・インコーポレーテッドGenentech,Inc.
发明人： DE SAUVAGE FREDERIC J , KLEIN ROBERT D , PHILLIPS HEIDI S , ROSENTHAL ARNON
IPC分类号： C12Q1/48 , G01N33/68 , A61K39/395 , A61K45/00 , A61P1/02 , A61P1/10 , A61P11/06 , A61P17/02 , A61P25/02 , A61P25/06 , A61P27/02 , C07K14/705 , C07K14/71 , C07K16/28 , C07K19/00 , C12N1/19 , C12N1/21 , C12N5/10 , C12N15/09 , C12N15/12 , C12Q1/42 , G01N33/543 , G01N33/573
CPC分类号： C07K16/2863 , C07K14/71 , C07K2317/75 , C07K2319/00 , C12Q1/485 , G01N33/573 , G01N33/74 , G01N2500/04 , G01N2500/10
摘要： PROBLEM TO BE SOLVED: To provide a new method for identification and isolation of a DNA, and to provide a new method for recombinant production of polypeptide characterized by the presence of a GFRα3 sequence which is a new α-subunit receptor. SOLUTION: Provided is a mammalian GFRα3, a new α-subunit receptor of the GDNF (i.e. GFR) receptor family, nucleotide sequences including expressed sequence tags (ESTs), oligonucleotide probes, polypeptides, vectors and host cells, and immunoadhesions and antibodies to the mammalian GFRα3. Provided, further, is an assay for measuring activation of an α-subunit receptor by detecting tyrosine kinase receptor activation (i.e., autophosphorylation) or other activities related to ligand-induced α-subunit receptor homo-dimerization or homo-oligomerization. COPYRIGHT: (C)2009,JPO&INPIT
摘要翻译：要解决的问题：提供用于鉴定和分离DNA的新方法，并提供重组产生多肽的新方法，其特征在于存在作为新α亚单位受体的GFRα3序列。解决方案：提供了哺乳动物GFRα3，GDNF（即GFR）受体家族的新α亚单位受体，包括表达序列标签（EST），寡核苷酸探针，多肽，载体和宿主细胞的核苷酸序列和免疫粘附和对哺乳动物GFRα3的抗体。此外，还提供了通过检测酪氨酸激酶受体活化（即自身磷酸化）或与配体诱导的α-亚基受体均二聚化或同型齐聚相关的其它活性来测定α-亚单位受体活化的测定法。版权所有（C）2009，JPO＆INPIT

4. 发明专利

JP2005046146A Promotion or inhibition of angiogenesis and cardiovascularization 有权
标题翻译：促进或抑制血液生成和心血管化
公开(公告)号：JP2005046146A
公开(公告)日：2005-02-24
申请号：JP2004212340
申请日：2004-07-20
申请人： Genentech Inc , ジェネンテック・インコーポレーテッドGenentech,Inc.
发明人： ASHKENAZI AVI J , BAKER KEVIN P , FERRARA NAPOLEONE , GERBER HANSPETER , HILLAN KENNETH J , GODDARD AUDREY , PAUL J GODOWSKI , GURNEY AUSTIN L , KLEIN ROBERT D , SOPHIA S KUO , PAONI NICHOLAS F , SMITH VICTORIA , WATANABE COLIN K , WILLIAMS P MICKEY , WOOD WILLIAM I
IPC分类号： G01N33/50 , A61K20060101 , A61K31/7088 , A61K31/711 , A61K38/00 , A61K38/17 , A61K39/395 , A61K45/00 , A61K48/00 , A61P7/00 , A61P9/00 , A61P9/04 , A61P9/10 , A61P17/00 , A61P17/02 , A61P35/00 , C07K14/47 , C07K14/515 , C07K14/52 , C07K16/18 , C07K16/22 , C07K16/24 , C07K19/00 , C12N1/15 , C12N1/19 , C12N1/21 , C12N5/10 , C12N7/00 , C12N15/09 , C12N15/11 , C12N15/12 , C12N15/867 , C12P21/02 , C12P21/08 , C12Q1/02 , C12Q1/68 , C12R1/19 , C12R1/645 , C12R1/93 , G01N33/15 , G01N33/53 , G01N33/68
CPC分类号： C12N9/6408 , A61K38/00 , C07K14/47 , C07K14/4703 , C07K16/18 , C12N2799/026 , C12Y304/21034 , G01N2800/32
摘要： PROBLEM TO BE SOLVED: To provide a pharmaceutical composition for stimulating or inhibiting angiogenesis and/or cardiovascularization in a mammal, and to provide a method for using the same. SOLUTION: This pharmaceutical composition is based on a polypeptide which is identified for one or more uses thereof or an antagonist thereto. Disease is diagnosed, prevented, or treated by the composition, wherein the disease includes trauma, such as a wound, cancer of various kinds, and vascular disease including atherosclerosis and cardiomegaly. Further, a new peptide and a nucleic acid molecule encoding the polypeptide are provided in the specification, respectively. Furthermore, a vector comprising a sequence of the nucleic acid, a host cell comprising the same, a chimeric molecule comprising the polypeptide which is fused with a heterologous polypeptide, an antibody coupling with the polypeptide, and a method for producing the polypeptide are provided, respectively. COPYRIGHT: (C)2005,JPO&NCIPI
摘要翻译：待解决的问题：提供一种用于刺激或抑制哺乳动物血管生成和/或心血管化的药物组合物，并提供使用该组合物的方法。解决方案：该药物组合物基于鉴定其一种或多种用途或其拮抗剂的多肽。疾病被组合物诊断，预防或治疗，其中疾病包括创伤，例如伤口，各种癌症，以及包括动脉粥样硬化和心脏肥大的血管疾病。此外，在本说明书中分别提供了新的肽和编码该多肽的核酸分子。此外，提供了包含核酸序列的载体，包含该序列的宿主细胞，包含与异源多肽融合的多肽的嵌合分子，与多肽偶联的抗体以及产生该多肽的方法，分别。版权所有（C）2005，JPO＆NCIPI

5. 发明申请

WO0032221A3 PROMOTION OR INHIBITION OF ANGIOGENESIS AND CARDIOVASCULARIZATION 审中-公开
标题翻译：促进或抑制血液生成和心血管化
公开(公告)号：WO0032221A3
公开(公告)日：2000-11-23
申请号：PCT/US9928313
申请日：1999-11-30
申请人： GENENTECH INC , ASHKENAZI AVI J , BAKER KEVIN P , FERRARA NAPOLEONE , GERBER HANSPETER , HILLAN KENNETH J , GODDARD AUDREY , GODOWSKI PAUL J , GURNEY AUSTIN L , KLEIN ROBERT D , KUO SOPHIA S , PAONI NICHOLAS F , SMITH VICTORIA , WATANABE COLIN K , WILLIAMS P MICKEY , WOOD WILLIAM I
发明人： ASHKENAZI AVI J , BAKER KEVIN P , FERRARA NAPOLEONE , GERBER HANSPETER , HILLAN KENNETH J , GODDARD AUDREY , GODOWSKI PAUL J , GURNEY AUSTIN L , KLEIN ROBERT D , KUO SOPHIA S , PAONI NICHOLAS F , SMITH VICTORIA , WATANABE COLIN K , WILLIAMS P MICKEY , WOOD WILLIAM I
IPC分类号： G01N33/50 , A61K20060101 , A61K31/7088 , A61K31/711 , A61K38/00 , A61K38/17 , A61K39/395 , A61K45/00 , A61K48/00 , A61P7/00 , A61P9/00 , A61P9/04 , A61P9/10 , A61P17/00 , A61P17/02 , A61P35/00 , C07K14/47 , C07K14/515 , C07K14/52 , C07K16/18 , C07K16/22 , C07K16/24 , C07K19/00 , C12N1/15 , C12N1/19 , C12N1/21 , C12N5/10 , C12N7/00 , C12N15/09 , C12N15/11 , C12N15/12 , C12N15/867 , C12P21/02 , C12P21/08 , C12Q1/02 , C12Q1/68 , C12R1/19 , C12R1/645 , C12R1/93 , G01N33/15 , G01N33/53 , G01N33/68 , C12N15/62
CPC分类号： C12N9/6408 , A61K38/00 , C07K14/47 , C07K14/4703 , C07K16/18 , C12N2799/026 , C12Y304/21034 , G01N2800/32
摘要： Compositions and methods are disclosed for stimulating or inhibiting angiogenesis and/or cardiovascularization in mammals, including humans. Pharmaceutical compositions are based on polypeptides or antagonists thereto that have been identified for one or more of these uses. Disorders that can be diagnosed, prevented, or treated by the compositions herein include trauma such as wounds, various cancers, and disorders of the vessels including atherosclerosis and cardiac hypertrophy. In addition, the present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.
摘要翻译：公开了用于刺激或抑制哺乳动物（包括人）中的血管发生和/或心血管化的组合物和方法。药物组合物基于已被鉴定为一种或多种这些用途的多肽或其拮抗剂。可以通过本文组合物诊断，预防或治疗的疾病包括创伤，例如创伤，各种癌症和血管障碍，包括动脉粥样硬化和心脏肥大。此外，本发明涉及新型多肽和编码那些多肽的核酸分子。本文还提供了包含那些核酸序列的载体和宿主细胞，包含与异源多肽序列融合的本发明的多肽的嵌合多肽分子，与本发明的多肽结合的抗体以及本发明的多肽的制备方法发明。

6. 发明申请

WO0021996A3 METHODS AND COMPOSITIONS FOR INHIBITING NEOPLASTIC CELL GROWTH 审中-公开
标题翻译：抑制肿瘤细胞生长的方法和组合物
公开(公告)号：WO0021996A3
公开(公告)日：2000-11-09
申请号：PCT/US9923089
申请日：1999-10-05
申请人： GENENTECH INC , ASHKENAZI AVI , GODDARD AUDREY , GURNEY AUSTIN L , KLEIN ROBERT D , NAPIER MARY , WOOD WILLIAM I , YUAN JEAN
发明人： ASHKENAZI AVI , GODDARD AUDREY , GURNEY AUSTIN L , KLEIN ROBERT D , NAPIER MARY , WOOD WILLIAM I , YUAN JEAN
IPC分类号： G01N33/50 , A61K38/00 , A61K39/395 , A61K45/00 , A61K45/06 , A61P25/00 , A61P29/00 , A61P35/00 , A61P37/02 , C07K14/47 , C12N15/09 , G01N33/15 , G01N33/53 , C12N15/12 , A61K38/17 , C07K16/18 , C12N15/62
CPC分类号： C07K14/47 , A61K38/00 , C07K2319/00
摘要： The present invention concerns methods and compositions for inhibiting neoplastic cell growth. In particular, the present invention concerns antitumor compositions and methods for the treatment of tumors. The invention further concerns screening methods for identifying growth inhibitory, e.g., antitumor compounds.
摘要翻译：本发明涉及用于抑制肿瘤细胞生长的方法和组合物。具体而言，本发明涉及用于治疗肿瘤的抗肿瘤组合物和方法。本发明还涉及鉴定生长抑制性的筛选方法，例如抗肿瘤化合物。

7. 发明申请

WO0053760A3 METHOD OF PREVENTING THE DEATH OF RETINAL NEURONS AND TREATING OCULAR DISEASES 审中-公开
标题翻译：预防神经元死亡和治疗眼部疾病的方法
公开(公告)号：WO0053760A3
公开(公告)日：2001-01-18
申请号：PCT/US0006319
申请日：2000-03-10
申请人： GENENTECH INC , FERRARA NAPOLEONE , GODDARD AUDREY , GURNEY AUSTIN L , HEBERT CAROLINE , HENZEL WILLIAM J , KABAKOFF RHONA C , KLEIN ROBERT D , KLJAVIN IVAR J , KUO SOPHIA S , FLEUR MONIQUE , WOOD WILLIAM I
发明人： FERRARA NAPOLEONE , GODDARD AUDREY , GURNEY AUSTIN L , HEBERT CAROLINE , HENZEL WILLIAM J , KABAKOFF RHONA C , KLEIN ROBERT D , KLJAVIN IVAR J , KUO SOPHIA S , LA FLEUR MONIQUE , WOOD WILLIAM I
IPC分类号： C07K14/47 , C12N15/12 , A61K38/17 , C07K14/52 , C07K16/18 , C12N15/62
CPC分类号： C07K14/4703 , C07K14/47 , C07K2317/24 , C07K2319/00 , C12N2799/026
摘要： The present invention relates to the use of PRO200 (VEGF-E), PRO540, PRO846, PRO617, PRO538 (GFR alpha 3), PRO3664 (GFR alpha 3) or PRO770 (hFIZZ-1) polypeptides to delay, prevent or rescue retinal neurons, including photoreceptors, other retinal cells or supportive cells (e.g Müller cells or RPE cells) from injury and degradation. Conditions comprehended by treatment of the present PRO200 (VEGF-E), PRO540, PRO846, PRO617, PRO538 (GFR alpha 3), PRO3664 (GFR alpha 3) or PRO770 (hFIZZ-1) polypeptides (including variants), antibodies, compositions and articles of manufacture include: retinal detachment, age-related and other maculopathies, photic retinopathies, surgery-induced retinopathies (either mechanically or light-induced), toxic retinopathies including those resulting from foreign bodies in the eye, diabetic retinpathies, retinpathy of prematurity, viral retinopathies such as CMV or HIV retinopathy related to AIDS, uveitis, ischemic retinopathies due to venous or arterial occlusion or other vascular disorder, retinopathies due to trauma or penetrating lesions of the eye, peripheral vitreoretinopathy, and inherited retinal degenerations. Exemplary retinal degenerations include e.g., hereditary spastic paraplegia with retinal degeneration (Kjellin and Barnard-Scholz syndromes), retinitis pigmentosa, Stargardt disease, Usher syndrome (retinitis pigmentosa with congenital hearing loss), and Refsum syndrome (retinitis pigmentosa, hereditary hearing loss, and polyneuropathy). Additional disorders which result in death of retinal neurons include, retinal tears, detachment of the retina and pigment epithelium, degenerative myopia, acute retinal necrosis syndrome (ARN), traumatic chorioretinopathies or contusion (Purtscher's Retinopathy) and edema.
摘要翻译：本发明涉及PRO200（VEGF-E），PRO540，PRO846，PRO617，PRO538（GFRα3），PRO3664（GFRα3）或PRO770（hFIZZ-1）多肽延迟，预防或挽救视网膜神经元的用途，包括光感受器，其他视网膜细胞或支持细胞（如Müller细胞或RPE细胞）的损伤和降解。通过治疗本PROTIN（VEGF-E），PRO540，PRO846，PRO617，PRO538（GFRα3），PRO3664（GFRα3）或PRO770（hFIZZ-1）多肽（包括变体），抗体，组合物和制造产品包括：视网膜脱离，年龄相关性和其他黄斑病，光视网膜病变，手术诱导的视网膜病变（机械或光诱导），有毒视网膜病变，包括由眼睛异物引起的视网膜病变，糖尿病视网膜病变，早产儿视网膜病变，与AIDS相关的病毒性视网膜病变或HIV视网膜病变，葡萄膜炎，由于静脉或动脉闭塞或其他血管障碍引起的缺血性视网膜病变，由于外伤或穿透性眼睛损伤引起的视网膜病变，外周性玻璃体视网膜病变和遗传性视网膜变性。示例性视网膜变性包括例如具有视网膜变性的遗传性痉挛性截瘫（Kjellin和Barnard-Scholz综合征），色素性视网膜炎，Stargardt病，Usher综合征（具有先天性听力损失的色素性视网膜炎）和Refsum综合征（色素性视网膜炎，遗传性听力损失和多发性神经病）。导致视网膜神经元死亡的其他病症包括视网膜撕裂，视网膜和色素上皮剥离，退行性近视，急性视网膜坏死综合征（ARN），创伤性脉络膜视网膜病变或挫伤（Purtscher's Retinopathy）和水肿。

8. 发明申请

WO9949039A3 GFR alpha 3 AND ITS USES 审中-公开
标题翻译： GFRα3及其用途
公开(公告)号：WO9949039A3
公开(公告)日：2000-02-10
申请号：PCT/US9906098
申请日：1999-03-19
申请人： GENENTECH INC
发明人： DE SAUVAGE FREDERIC J , KLEIN ROBERT D , PHILLIPS HEIDI S , ROSENTHAL ARNON
IPC分类号： G01N33/68 , A61K39/395 , A61K45/00 , A61P1/02 , A61P1/10 , A61P11/06 , A61P17/02 , A61P25/02 , A61P25/06 , A61P27/02 , C07K14/71 , C07K16/28 , C07K19/00 , C12N1/19 , C12N1/21 , C12N5/10 , C12N15/09 , C12N15/12 , C12Q1/42 , G01N33/573 , C12N15/70 , C12N15/81 , C12N15/85
CPC分类号： C07K16/2863 , C07K14/71 , C07K2317/75 , C07K2319/00 , C12Q1/485 , G01N33/573 , G01N33/74 , G01N2500/04 , G01N2500/10
摘要： The present invention relates to nucleotide sequences, including expressed sequence tags (ESTS'S), oligonucleotide probes, polypeptides, vectors and host cells expressing, and immunoadhesions and antibodies to mammalian GFRx3, a x-subunit receptor of the GDNF (i.e. GFR) receptor family. It further relates to an assay for measuring activation of an x-subunit receptor by detecting tyrosine kinase receptor activation (i.e., autophosphorylation) or other activities related to ligand-induced x-subunit receptor homo-dimerization or homo-oligomerization.
摘要翻译：本发明涉及核苷酸序列，包括表达序列标签（ESTS'S），寡核苷酸探针，多肽，载体和表达哺乳动物GFRx3，GDNF（即GFR）受体家族的x亚单位受体的免疫粘附和抗体的宿主细胞。它进一步涉及通过检测酪氨酸激酶受体活化（即自磷酸化）或与配体诱导的x-亚基受体均二聚化或同型寡聚化相关的其它活性来测量x-亚基受体活化的测定。

9. 发明申请

WO9733912A2 USES OF GDNF AND GDNF RECEPTOR 审中-公开
标题翻译： GDNF和GDNF受体的使用
公开(公告)号：WO9733912A2
公开(公告)日：1997-09-18
申请号：PCT/US9704363
申请日：1997-03-13
申请人： GENENTECH INC , KLEIN ROBERT D , MOORE MARK W , ROSENTHAL ARNON , RYAN ANNE M
发明人： KLEIN ROBERT D , MOORE MARK W , ROSENTHAL ARNON , RYAN ANNE M
IPC分类号： C12N15/09 , A01K67/027 , A61K31/00 , A61K38/00 , A61K39/395 , A61P13/00 , A61P13/12 , C07K14/71 , C07K16/00 , C07K16/22 , C07K16/28 , C07K19/00 , C12N5/02 , C12N5/10 , C12P21/08 , G01N33/53 , G01N33/566
CPC分类号： C07K14/71 , A01K2217/05 , A61K38/00 , C07K16/22 , C07K2319/00
摘要： GDNFR alpha , GDNFR alpha extracellular domain (ECD), GDNFR alpha variants, chimeric GDNFRae (e.g., GDNFR alpha immunoadhesin), and antibodies which bind thereto (including agonist and neutralizing antibodies) are disclosed. Various uses for these molecules are described, including methods to modulate cell activity and survival by response to GDNFR alpha -ligands, for example GDNF, by providing GDNFR alpha to the cell. Also provided are methods for using GDNFR alpha , GDNF, or agonists thereof, separately or in complex, to treat kidney diseases.
摘要翻译：公开了GDNFRα，GDNFRα细胞外结构域（ECD），GDNFRα变体，嵌合GDNFRae（例如，GDNFRα免疫粘附素）和与其结合的抗体（包括激动剂和中和抗体）。描述了这些分子的各种用途，包括通过向细胞提供GDNFRα来通过响应于GDNFRα-配体（例如GDNF）来调节细胞活性和存活的方法。还提供了使用GDNFRα，GDNF或其分别或复合物的激动剂来治疗肾脏疾病的方法。

10. 发明专利

CA2246768C USES OF GDNF AND GDNF RECEPTOR 未知
公开(公告)号：CA2246768C
公开(公告)日：2013-12-31
申请号：CA2246768
申请日：1997-03-13
申请人： GENENTECH INC
发明人： KLEIN ROBERT D , MOORE MARK W , ROSENTHAL ARNON , RYAN ANNE M
IPC分类号： C12N15/09 , C12N15/18 , A01K67/027 , A61K31/00 , A61K38/00 , A61K38/18 , A61K39/395 , A61P13/00 , A61P13/12 , C07K1/22 , C07K14/71 , C07K16/00 , C07K16/22 , C07K16/28 , C07K19/00 , C12N5/02 , C12N5/10 , C12N15/62 , C12P21/08 , G01N33/53 , G01N33/566
摘要： GDNFR.alpha., GDNFR.alpha. extracellular domain (ECD), GDNFR.alpha. variants, chimeric GDNFR.alpha. (e.g., GDNFR.alpha. immunoadhesin), and antibodies which bind thereto (including agonist and neutralizing antibodies) are disclosed. Various uses for these molecules are described, including methods to modulate cell activity and survival by response to GDNFR.alpha. -ligands, for example GDNF, by providing GDNFR.alpha. to the cell. Also provided are methods for using GDNFR.alpha., GDNF, or agonists thereof, separately or in complex, to treat kidney diseases.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式